Lizcova L, Prihodova E, Pavlistova L, Svobodova K, Mejstrikova E, Hrusak O
Mol Cytogenet. 2024; 17(1):14.
PMID: 38783324
PMC: 11118568.
DOI: 10.1186/s13039-024-00682-4.
Rashid M, Alasiri A, Al Balwi M, Alkhaldi A, Alsuhaibani A, Alsultan A
Genes (Basel). 2021; 12(9).
PMID: 34573308
PMC: 8470887.
DOI: 10.3390/genes12091326.
van Dijk A, Hoff F, Qiu Y, Chandra J, Jabbour E, de Bont E
Clin Epigenetics. 2021; 13(1):21.
PMID: 33509276
PMC: 7841917.
DOI: 10.1186/s13148-021-01011-x.
Liu X, Zou Y, Ruan M, Chang L, Chen X, Wang S
Front Cell Infect Microbiol. 2020; 10:558799.
PMID: 33178621
PMC: 7596659.
DOI: 10.3389/fcimb.2020.558799.
Kerketta L, Ghosh K, Nadkarni A, Madkaikar M, Vundinti B
In Vivo. 2017; 31(2):215-220.
PMID: 28358703
PMC: 5411748.
DOI: 10.21873/invivo.11048.
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Cante-Barrett K, Spijkers-Hagelstein J, Buijs-Gladdines J, Uitdehaag J, Smits W, van der Zwet J
Leukemia. 2016; 30(9):1832-43.
PMID: 27174491
PMC: 5240021.
DOI: 10.1038/leu.2016.83.
Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway.
Ouzounoglou E, Dionysiou D, Stamatakos G
BMC Syst Biol. 2016; 10:23.
PMID: 26932523
PMC: 4774111.
DOI: 10.1186/s12918-016-0264-5.
Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A, Peters G, van Woerden N, Dubbelman B, Escherich G, Schmiegelow K
J Hematol Oncol. 2015; 8:61.
PMID: 26022503
PMC: 4455979.
DOI: 10.1186/s13045-015-0158-9.
MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
Schotte D, de Menezes R, Akbari Moqadam F, Mohammadi Khankahdani L, Lange-Turenhout E, Chen C
Haematologica. 2011; 96(5):703-11.
PMID: 21242186
PMC: 3084917.
DOI: 10.3324/haematol.2010.026138.
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
Pui C, Carroll W, Meshinchi S, Arceci R
J Clin Oncol. 2011; 29(5):551-65.
PMID: 21220611
PMC: 3071256.
DOI: 10.1200/JCO.2010.30.7405.
Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D, Lange-Turenhout E, Stumpel D, Stam R, Buijs-Gladdines J, Meijerink J
Haematologica. 2010; 95(10):1675-82.
PMID: 20494936
PMC: 2948092.
DOI: 10.3324/haematol.2010.023481.
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Juszczynski P, Rodig S, Ouyang J, ODonnell E, Takeyama K, Mlynarski W
Clin Cancer Res. 2010; 16(7):2122-30.
PMID: 20332322
PMC: 2920144.
DOI: 10.1158/1078-0432.CCR-09-2765.
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J, Ware C, Efferson C, ONeil J, Rao S, Qu X
Br J Pharmacol. 2009; 158(5):1183-95.
PMID: 19775282
PMC: 2782329.
DOI: 10.1111/j.1476-5381.2009.00389.x.